ZIVO
Zivo Bioscience, Inc.Company Information
- Company Name
- Zivo Bioscience, Inc.
- CIK
- CIK0001101026
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ZIVO: OTC, ZIVOW: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ZIVO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-17
- Last sale
- 2025-04-08
- Shares purchased (TTM)
- 218,114
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 4,964
- Shares outstanding
- 3,832,327
- Ownership
- 0.13%
Earnings Market Reaction
- Filing date
- 2025-11-14
- Price on filing date
- —
- 1-month reaction
- -18.37%
- 3-month reaction
- -14.29%
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Assets Current | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 2 | ||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | ||||||
| Accounts Receivable Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Other Assets | ||||||||||||||||||
| Other Assets | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Security Deposit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Customer Deposits Current | 0 | 0 | 0 | - | 0 | 0 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 4 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 2 | ||||||
| Loans Payable | - | - | - | - | 0 | 0 | 0 | - | 1 | 1 | 1 | - | ||||||
| Notes Payable Current | 0 | - | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Convertible Debt Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Notes Payable | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | ||||||
| Interest Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Accrued Liabilities Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Lease Deposit Liability | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Notes Payable | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 4 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 2 | ||||||
Commitments And Contingencies Disclosure | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 141 | 140 | 140 | 136 | 133 | 131 | 123 | 121 | 121 | 117 | 116 | 116 | ||||||
| Stockholders Equity | -3 | -3 | -2 | -1 | -2 | -2 | -2 | -2 | -1 | -3 | -2 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -144 | -143 | -141 | -137 | -135 | -133 | -125 | -124 | -122 | -120 | -118 | -116 | ||||||
| Liabilities And Stockholders Equity | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 25 | 25 | 25 | - | 25 | 25 | 25 | 25 | 25 | 150 | 150 | 25 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | 3 | 3 | 3 | - | 2 | 9 | 150 | - | ||||||
| Common Stock Shares Issued | 4 | 4 | 4 | - | - | - | - | 2 | - | - | - | 2 | ||||||
| Shares Outstanding | 4 | 4 | 4 | - | 3 | 3 | 3 | 2 | 2 | 9 | 9 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZivo Bioscience, Inc. (ZIVO) — SEC Financial Statements & Analysis
Zivo Bioscience, Inc. (ZIVO) is a biological products, (no diagnostic substances) company, incorporated in NV. Zivo Bioscience, Inc. trades on OTC as: ZIVO, ZIVOW. Zivo Bioscience, Inc. (ZIVO)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14. Based on that filing, Zivo Bioscience, Inc. carries a market cap of $61.28M, a P/E ratio of -7.22x, a P/B ratio of -18.65x, a P/S ratio of 320.25x, an enterprise value of $61.61M, and an EV/EBITDA multiple of -7.29x. On profitability, it posts a gross margin of 12.72%, an operating margin of -4419.46%, a net margin of -4434.85%, a Return on Equity (ROE) of 316.07%, and a Return on Assets (ROA) of -1608.63%. Per share, it reports EPS of $-2.21, diluted EPS of $-2.22, free cash flow per share of $-0.80, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 304.11% year-over-year, net income growth of -38.02% year-over-year, and EPS growth of -43.55% year-over-year. On the balance sheet, it maintains a current ratio of 0.08x, a quick ratio of 0.02x, working capital of $-3.33M, a debt-to-equity ratio of -1.17x, a debt ratio of 6.87, an interest coverage ratio of -372.22x, free cash flow of $-3.08M (TTM), and net debt of $330.18K. Figures sourced from SEC EDGAR.
- Market Cap
- $61.28M
- P/E TTM
- -7.22x
- EPS TTM
- $-2.21
- P/B TTM
- -18.65x
- ROE TTM
- 316.07%
- ROA TTM
- -1608.63%
- Debt To Equity
- -1.17x
- Free Cash Flow TTM
- $-3.08M
- Net Revenue TTM Growth 1Y
- 304.11%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Zivo Bioscience, Inc. in?
Zivo Bioscience, Inc. (ZIVO) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ZIVO trade on?
Zivo Bioscience, Inc. (ZIVO) trades on the OTC.
Where is Zivo Bioscience, Inc. incorporated?
Zivo Bioscience, Inc. is incorporated in NV.
When was Zivo Bioscience, Inc. (ZIVO)'s most recent SEC filing?
Zivo Bioscience, Inc. (ZIVO)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14.
What is ZIVO's market cap?
Zivo Bioscience, Inc. (ZIVO) has a market capitalization of $61.28M as of 2025-09-30.
What is ZIVO's EPS (earnings per share)?
Zivo Bioscience, Inc. (ZIVO)'s trailing twelve month EPS is $-2.21 as of 2025-09-30.
What is ZIVO's ROE (return on equity)?
Zivo Bioscience, Inc. (ZIVO)'s trailing twelve month Return on Equity (ROE) is 316.07% as of 2025-09-30.
What is ZIVO's ROA (return on assets)?
Zivo Bioscience, Inc. (ZIVO)'s trailing twelve month Return on Assets (ROA) is -1608.63% as of 2025-09-30.
What is ZIVO's EV/EBITDA?
Zivo Bioscience, Inc. (ZIVO)'s trailing twelve month EV/EBITDA is -7.29x as of 2025-09-30.